See more : Tonymoly Co., Ltd (214420.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Novo Nordisk A/S (NVO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Novo Nordisk A/S, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Resource Mining Corporation Limited (RMI.AX) Income Statement Analysis – Financial Results
- Neola Medical AB (publ) (NEOLA.ST) Income Statement Analysis – Financial Results
- Paranovus Entertainment Technology Ltd. (PAVS) Income Statement Analysis – Financial Results
- Alkhabeer REIT Fund (4348.SR) Income Statement Analysis – Financial Results
- Interregional Distribution Grid Company of Urals, Joint Stock Company (MRKU.ME) Income Statement Analysis – Financial Results
Novo Nordisk A/S (NVO)
About Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 232.26B | 176.95B | 140.80B | 126.95B | 122.02B | 111.83B | 111.70B | 111.78B | 107.93B | 88.81B | 83.57B | 78.03B | 66.35B | 60.78B | 51.08B | 45.67B | 41.89B | 38.75B | 33.71B | 29.23B | 26.61B | 25.15B | 23.72B | 20.82B | 20.94B | 17.91B | 16.98B | 14.90B | 13.71B | 13.52B | 13.15B | 10.67B | 9.83B | 8.33B | 7.62B | 5.63B | 5.03B | 4.19B | 4.16B |
| Cost of Revenue | 35.77B | 28.45B | 23.66B | 20.93B | 20.09B | 17.62B | 17.63B | 17.18B | 16.19B | 14.56B | 14.14B | 13.47B | 12.59B | 11.68B | 10.44B | 10.13B | 9.80B | 9.59B | 9.17B | 8.11B | 7.46B | 6.62B | 5.96B | 4.38B | 5.05B | 4.39B | 4.72B | 4.17B | 3.83B | 3.83B | 6.41B | 2.53B | 4.80B | 4.13B | 3.76B | 2.72B | 2.59B | 3.29B | 2.07B |
| Gross Profit | 196.50B | 148.51B | 117.14B | 106.01B | 101.93B | 94.21B | 94.06B | 94.60B | 91.74B | 74.24B | 69.43B | 64.56B | 53.76B | 49.10B | 40.64B | 35.53B | 32.09B | 29.16B | 24.55B | 21.13B | 19.15B | 18.53B | 17.75B | 16.44B | 15.89B | 13.52B | 12.26B | 10.74B | 9.88B | 9.68B | 6.74B | 8.14B | 5.03B | 4.21B | 3.85B | 2.91B | 2.44B | 893.58M | 2.09B |
| Gross Profit Ratio | 84.60% | 83.92% | 83.20% | 83.51% | 83.54% | 84.25% | 84.21% | 84.63% | 85.00% | 83.60% | 83.08% | 82.74% | 81.03% | 80.78% | 79.56% | 77.81% | 76.60% | 75.26% | 72.81% | 72.27% | 71.96% | 73.66% | 74.85% | 78.96% | 75.89% | 75.50% | 72.20% | 72.04% | 72.07% | 71.64% | 51.26% | 76.32% | 51.22% | 50.49% | 50.59% | 51.75% | 48.49% | 21.34% | 50.14% |
| Research & Development | 32.44B | 24.05B | 17.77B | 15.46B | 14.22B | 14.81B | 14.01B | 14.56B | 13.61B | 13.76B | 11.73B | 10.90B | 9.63B | 9.60B | 7.86B | 7.87B | 8.55B | 6.32B | 5.07B | 4.38B | 4.20B | 4.13B | 3.96B | 3.22B | 3.36B | 3.40B | 2.77B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 4.86B | 4.47B | 4.05B | 3.96B | 4.01B | 3.92B | 3.78B | 3.96B | 3.86B | 3.54B | 3.51B | 3.31B | 3.25B | 3.72B | 2.76B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 56.74B | 46.22B | 37.01B | 32.93B | 31.82B | 29.40B | 28.34B | 28.38B | 28.31B | 23.22B | 23.38B | 21.54B | 19.00B | 18.20B | 15.42B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 61.60B | 50.68B | 41.06B | 36.89B | 35.83B | 33.31B | 32.12B | 32.34B | 32.17B | 26.76B | 26.89B | 24.86B | 22.25B | 21.92B | 18.18B | 15.82B | 14.90B | 14.00B | 11.79B | 10.30B | 9.67B | 9.42B | 9.06B | 7.93B | 7.50B | 6.59B | 6.02B | 7.69B | 6.87B | 6.79B | 3.99B | 6.29B | 3.04B | 2.63B | 2.33B | 1.65B | 1.52B | 0.00 | 1.15B |
| Other Expenses | -119.00M | -1.03B | -332.00M | -460.00M | -600.00M | -1.15B | -1.04B | -737.00M | -3.48B | -770.00M | -682.00M | -666.00M | 0.00 | 0.00 | 0.00 | -572.36M | -322.18M | -271.23M | -397.15M | -581.71M | -1.12B | -997.95M | -860.46M | 1.03B | 1.43B | 1.47B | 1.14B | 1.07B | 1.14B | 1.06B | 799.09M | 693.74M | 591.94M | 520.42M | 471.78M | 323.77M | 266.42M | 224.68M | 199.90M |
| Operating Expenses | 93.92B | 73.70B | 58.50B | 51.89B | 49.45B | 46.97B | 45.10B | 46.17B | 42.30B | 39.75B | 37.94B | 35.09B | 31.88B | 31.52B | 26.05B | 23.12B | 23.13B | 20.04B | 16.47B | 14.10B | 12.75B | 12.56B | 12.16B | 12.19B | 12.28B | 11.46B | 9.93B | 8.76B | 8.01B | 7.84B | 4.79B | 6.99B | 3.63B | 3.15B | 2.80B | 1.98B | 1.79B | 224.68M | 1.35B |
| Cost & Expenses | 129.69B | 102.15B | 82.16B | 72.82B | 69.54B | 64.58B | 62.73B | 63.35B | 58.48B | 54.31B | 52.08B | 48.55B | 44.47B | 43.20B | 36.49B | 33.26B | 32.93B | 29.63B | 25.64B | 22.20B | 20.22B | 19.18B | 18.12B | 16.57B | 17.33B | 15.84B | 14.65B | 12.92B | 11.84B | 11.68B | 11.20B | 9.51B | 8.43B | 7.28B | 6.57B | 4.69B | 4.38B | 3.52B | 3.43B |
| Interest Income | 1.07B | 239.00M | 2.89B | 337.00M | 65.00M | 51.00M | 69.00M | 52.00M | 85.00M | 167.00M | 56.00M | 125.00M | 514.00M | 382.00M | 375.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 739.00M | 378.00M | 2.45B | 390.00M | 220.00M | 85.00M | 90.00M | 65.00M | 6.05B | 563.00M | 55.00M | 1.79B | 959.00M | 2.06B | 1.27B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 9.41B | 6.60B | 5.31B | 5.28B | 4.68B | 3.81B | 2.87B | 2.65B | 3.04B | 3.60B | 3.57B | 2.82B | 20.00M | 2.85B | 3.27B | 2.08B | 1.90B | 1.64B | 1.21B | 1.44B | 1.63B | 1.33B | 208.85M | 665.76M | 1.19B | 1.47B | 1.14B | 1.07B | 1.14B | 1.06B | 799.09M | 693.74M | 591.94M | 520.42M | 471.78M | 323.77M | 266.42M | 224.68M | 199.90M |
| EBITDA | 113.33B | 76.41B | 64.83B | 58.57B | 56.31B | 51.57B | 51.69B | 50.58B | 49.58B | 38.09B | 35.25B | 30.44B | 24.94B | 21.25B | 17.80B | 14.48B | 11.97B | 10.76B | 9.29B | 8.47B | 8.02B | 6.05B | 5.81B | 4.91B | 4.81B | 2.09B | 2.31B | 2.15B | 2.61B | 2.42B | 2.26B | 812.29M | 1.54B | 1.19B | 1.27B | 1.02B | 708.41M | 675.51M | 673.20M |
| EBITDA Ratio | 48.79% | 46.36% | 47.98% | 47.43% | 47.36% | 45.75% | 46.70% | 46.18% | 48.63% | 42.90% | 41.95% | 41.39% | 33.75% | 35.77% | 35.63% | 31.71% | 25.91% | 27.76% | 27.54% | 28.98% | 22.57% | 24.06% | 24.48% | 23.58% | 22.94% | 11.68% | 13.59% | 14.45% | 19.05% | 17.91% | 17.22% | 7.61% | 15.70% | 14.23% | 16.61% | 18.05% | 14.09% | 16.13% | 16.19% |
| Operating Income | 102.57B | 74.81B | 58.64B | 54.13B | 52.48B | 47.25B | 48.97B | 48.43B | 49.44B | 34.49B | 31.49B | 29.47B | 22.37B | 18.89B | 14.93B | 12.40B | 8.95B | 9.12B | 8.08B | 7.03B | 4.38B | 4.72B | 5.60B | 4.24B | 3.62B | 623.53M | 1.17B | 1.09B | 1.47B | 1.37B | 1.47B | 118.55M | 950.89M | 664.82M | 793.56M | 692.21M | 442.00M | 450.83M | 473.30M |
| Operating Income Ratio | 44.16% | 42.28% | 41.65% | 42.64% | 43.01% | 42.25% | 43.84% | 43.33% | 45.81% | 38.84% | 37.68% | 37.77% | 33.72% | 31.08% | 29.24% | 27.16% | 21.38% | 23.53% | 23.95% | 24.05% | 16.46% | 18.77% | 23.60% | 20.39% | 17.26% | 3.48% | 6.86% | 7.29% | 10.74% | 10.10% | 11.14% | 1.11% | 9.67% | 7.98% | 10.42% | 12.30% | 8.79% | 10.77% | 11.38% |
| Total Other Income/Expenses | 2.10B | -5.75B | 436.00M | -996.00M | -3.93B | 367.00M | -287.00M | -634.00M | -5.96B | -396.00M | 1.05B | -1.66B | -449.00M | -605.00M | -945.00M | 320.95M | 2.03B | 45.20M | 144.99M | 477.44M | 1.18B | 1.57B | 417.70M | 601.59M | 340.08M | 3.12B | 2.01B | 1.44B | 681.11M | 565.52M | 407.02M | 1.55B | 511.52M | 473.05M | 255.71M | 213.09M | 255.44M | 337.76M | 403.38M |
| Income Before Tax | 104.67B | 69.06B | 59.08B | 53.13B | 48.55B | 47.62B | 48.68B | 47.80B | 43.48B | 34.10B | 32.54B | 27.81B | 21.93B | 18.29B | 13.99B | 12.73B | 10.98B | 9.17B | 8.22B | 7.51B | 7.58B | 6.29B | 6.01B | 4.84B | 3.96B | 3.75B | 3.17B | 2.53B | 2.15B | 1.93B | 1.87B | 1.67B | 1.46B | 1.14B | 1.05B | 905.31M | 697.44M | 788.58M | 876.68M |
| Income Before Tax Ratio | 45.07% | 39.03% | 41.96% | 41.85% | 39.79% | 42.58% | 43.58% | 42.76% | 40.29% | 38.39% | 38.94% | 35.64% | 33.05% | 30.09% | 27.39% | 27.87% | 26.22% | 23.65% | 24.38% | 25.68% | 28.48% | 25.01% | 25.36% | 23.28% | 18.88% | 20.91% | 18.67% | 16.97% | 15.71% | 14.29% | 14.24% | 15.68% | 14.88% | 13.66% | 13.77% | 16.08% | 13.87% | 18.83% | 21.08% |
| Income Tax Expense | 20.99B | 13.54B | 11.32B | 10.99B | 9.60B | 8.99B | 10.55B | 9.87B | 8.62B | 7.62B | 7.36B | 6.38B | 4.83B | 3.88B | 3.22B | 3.06B | 2.45B | 2.71B | 2.36B | 2.46B | 2.53B | 2.20B | 2.16B | 1.76B | 1.55B | 1.34B | 952.42M | 726.73M | 592.44M | 499.85M | 441.68M | 400.19M | 532.22M | 377.75M | 303.28M | 267.40M | 217.04M | 267.27M | 268.92M |
| Net Income | 83.68B | 55.53B | 47.76B | 42.14B | 38.95B | 38.63B | 38.13B | 37.93B | 34.86B | 26.48B | 25.18B | 21.43B | 17.10B | 14.40B | 10.77B | 9.67B | 8.54B | 6.45B | 5.86B | 5.05B | 4.87B | 4.09B | 3.85B | 3.09B | 2.41B | 2.41B | 2.22B | 1.80B | 1.56B | 1.43B | 1.43B | 1.27B | 930.19M | 760.12M | 745.99M | 637.91M | 480.40M | 521.32M | 607.76M |
| Net Income Ratio | 36.03% | 31.38% | 33.92% | 33.19% | 31.92% | 34.54% | 34.14% | 33.93% | 32.30% | 29.82% | 30.13% | 27.47% | 25.77% | 23.70% | 21.08% | 21.17% | 20.38% | 16.65% | 17.37% | 17.27% | 18.31% | 16.26% | 16.24% | 14.84% | 11.51% | 13.45% | 13.07% | 12.09% | 11.39% | 10.59% | 10.88% | 11.93% | 9.46% | 9.12% | 9.79% | 11.33% | 9.55% | 12.45% | 14.62% |
| EPS | 9.34 | 12.26 | 10.40 | 9.03 | 4.10 | 3.99 | 7.71 | 7.50 | 6.78 | 5.05 | 4.70 | 7.82 | 3.03 | 2.48 | 1.80 | 1.57 | 1.36 | 1.01 | 0.89 | 0.75 | 0.72 | 0.59 | 0.56 | 0.45 | 0.35 | 0.26 | 0.30 | 0.24 | 0.21 | 0.19 | 0.19 | 0.17 | 0.16 | 0.12 | 0.10 | 0.13 | 0.10 | 0.11 | 0.12 |
| EPS Diluted | 9.31 | 12.22 | 10.37 | 9.01 | 4.10 | 3.99 | 7.70 | 7.48 | 6.76 | 5.04 | 4.68 | 7.77 | 3.00 | 2.46 | 1.78 | 1.55 | 1.35 | 1.00 | 0.89 | 0.75 | 0.71 | 0.59 | 0.56 | 0.45 | 0.34 | 0.26 | 0.30 | 0.24 | 0.21 | 0.19 | 0.19 | 0.17 | 0.16 | 0.12 | 0.10 | 0.13 | 0.10 | 0.11 | 0.12 |
| Weighted Avg Shares Out | 4.48B | 4.53B | 4.59B | 4.67B | 4.75B | 4.84B | 4.96B | 5.07B | 5.16B | 5.26B | 5.39B | 5.52B | 5.65B | 5.81B | 5.99B | 3.09B | 3.15B | 3.21B | 3.28B | 3.38B | 3.42B | 3.46B | 3.44B | 3.46B | 3.80B | 3.80B | 3.77B | 3.74B | 3.76B | 3.74B | 3.76B | 3.76B | 5.83B | 3.13B | 4.03B | 5.16B | 5.08B | 5.07B | 5.02B |
| Weighted Avg Shares Out (Dil) | 4.49B | 4.54B | 4.61B | 4.68B | 4.76B | 4.85B | 4.96B | 5.07B | 5.16B | 5.26B | 5.39B | 5.52B | 5.70B | 5.85B | 6.04B | 3.11B | 3.18B | 3.23B | 3.29B | 3.39B | 3.44B | 3.49B | 3.47B | 3.47B | 3.80B | 3.80B | 3.77B | 3.74B | 3.76B | 3.74B | 3.76B | 3.76B | 5.83B | 3.13B | 4.03B | 5.16B | 5.08B | 5.07B | 5.02B |
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
Bagsværd, Denmark, 6 December 2024 — Today, the European Commission approved Novo Holdings A/S' acquisition of Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in New Jersey (US), as well as Novo Nordisk's subsequent acquisition of three manufacturing...
Novo Holdings' $16.5 bln Catalent buy wins EU antitrust approval
Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S. contract drug maker Catalent after EU regulators said they did not see any competition issues.
Structure CEO on the competitive landscape for oral GLP-1 drugs
Raymond Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk its oral GLP-1 offerings.
Novavax to Sell Czech Manufacturing Plant to Novo Nordisk for $200M
NVAX intends to use the payment from Novo to advance the development of its vaccine pipeline. The deal is expected to be closed by the end of this year.
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novo Nordisk to cut US list prices of two insulin products by more than 70%
Danish drug maker Novo Nordisk said on Thursday it will reduce the U.S. list prices of two insulin products by more than 70% from January of 2026.
Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial
Eli Lilly's (LLY) popular weight-loss drug Zepbound outperformed Wegovy, a competitor drug from Danish drugmaker Novo Nordisk (NVO), according to the results of a new clinical study released Wednesday.
Stock Of The Day: Where Will The Eli Lilly Rally End?
Shares of Eli Lilly and Company LLY are trading higher on Wednesday. The company said that its Zepbound drug was more effective in helping adults with obesity lose weight than Novo Nordisk A/S's NVO Wegovy.
Lilly's Zepbound Beats Novo's Wegovy in Weight-Loss Drug Trial
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S's Wegovy in the first head-to-head trial of the two blockbusters. In the study sponsored by Lilly, those on Zepbound lost an average of about 50 pounds over 72...
Eli Lilly's Weight-Loss Drug Zepbound Is Better than Novo's Wegovy, Study Finds
On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy, Lilly said.
Source: https://incomestatements.info
Category: Stock Reports